Compared with KIRC cohorts with decreased immune cells, the high STON1 group enriched with the anti-cancer immune cells B cells, CD4 + T cells, CD8 + T cells, and macrophages demonstrated a favorable prognosis. This evidence concerns the gene CD8A and cancer.